The European Committee for Treatment and Research in MS (ECTRIMS) annual meeting presented new data that helped to clarify the mode of action of anti-CD20 agents and address some safety issues that have arisen during the COVID-19 pandemic. Read More

A new study has found that a high proportion of MS patients with no evidence of disease activity (NEDA) in the first two years of treatment will experience relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) (Prosperini et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059). Read More